176 related articles for article (PubMed ID: 37192041)
1. Treatment outcomes and time to healing of medication-related osteonecrosis of the jaw based on image findings.
Yasui T; Nagamine H; Tanaka K; Kimura M; Karube T; Kawana H; Onizawa K
Dentomaxillofac Radiol; 2023 Jul; 52(5):20220352. PubMed ID: 37192041
[TBL] [Abstract][Full Text] [Related]
2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
3. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
4. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S
J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study.
Sakamoto Y; Sawada S; Kojima Y
Sci Rep; 2023 Aug; 13(1):12890. PubMed ID: 37558709
[TBL] [Abstract][Full Text] [Related]
6. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
Ristow O; Rückschloß T; Müller M; Berger M; Kargus S; Pautke C; Engel M; Hoffmann J; Freudlsperger C
J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
[TBL] [Abstract][Full Text] [Related]
7. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
8. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
9. The Type of Antiresorptive Treatment Influences the Time to Onset and the Surgical Outcome of Medication-Related Osteonecrosis of the Jaw.
Pautke C; Wick A; Otto S; Hohlweg-Majert B; Hoffmann J; Ristow O
J Oral Maxillofac Surg; 2021 Mar; 79(3):611-621. PubMed ID: 33166522
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
Oral Dis; 2022 Jan; 28(1):182-192. PubMed ID: 33254278
[TBL] [Abstract][Full Text] [Related]
11. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
[TBL] [Abstract][Full Text] [Related]
12. How does the clinical and tomographic appearance of MRONJ influences its treatment prognosis?
Moreno Rabie C; García-Larraín S; Contreras Diez de Medina D; Cabello-Salazar I; Fontenele RC; Van den Wyngaert T; Jacobs R
Dentomaxillofac Radiol; 2023 Nov; 52(8):20230304. PubMed ID: 37870051
[TBL] [Abstract][Full Text] [Related]
13. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Oral Dis; 2018 Mar; 24(1-2):238-242. PubMed ID: 29480596
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Drug Holidays of Antiresorptive Agents and Surgical Outcomes in Cancer Patients with Medication-Related Osteonecrosis of the Jaw.
Otsuru M; Soutome S; Omori K; Suyama K; Morishita K; Hayashida S; Murata M; Takagi Y; Sasaki M; Sumi M; Kojima Y; Sawada S; Sakamoto Y; Umeda M
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457491
[TBL] [Abstract][Full Text] [Related]
15. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
16. Medication-related osteonecrosis of the lower jaw without osteolysis on computed tomography images.
Kojima Y; Sawada S; Sakamoto Y
J Bone Miner Metab; 2024 Jan; 42(1):27-36. PubMed ID: 38194089
[TBL] [Abstract][Full Text] [Related]
17. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
[TBL] [Abstract][Full Text] [Related]
18. Risk factors associated with prognosis of patients with medication-related osteonecrosis of the jaw.
Tadokoro Y; Hasegawa T; Takeda D; Murakami A; Yatagai N; Arimoro S; Iwata E; Saito I; Kusumoto J; Akashi M
Head Neck; 2024 Feb; 46(2):282-290. PubMed ID: 37962011
[TBL] [Abstract][Full Text] [Related]
19. The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: A 12-year retrospective study of 129 patients.
Kaibuchi N; Hoshi K; Yamazaki A; Miyamoto-Sangu N; Akagi Y; Okamoto T
Bone Rep; 2021 Jun; 14():101072. PubMed ID: 33997149
[TBL] [Abstract][Full Text] [Related]
20. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.
Wick A; Bankosegger P; Otto S; Hohlweg-Majert B; Steiner T; Probst F; Ristow O; Pautke C
Clin Oral Investig; 2022 Mar; 26(3):2839-2852. PubMed ID: 34812959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
